Abstract
Genetic and epigenetic alterations of human chromosome 3, investigated by NotI-microarrays in seven types of epithelial cancers
Highlights
Fisher’s exact test and Chisquare criteria were used for analysis of methy lation and/or deletion frequencies in groups of tumors with different patho-morphological characteristics [2, 10,11,12,13,14,15,16,17,18]
We have reviewed and summarized the data from different cohorts and with different data calculations for colorectal, ovarian, renal, lung, breast, cervical and prostate cancers [2, 10,11,12,13,14,15,16,17,18]
Deletions and methylation were in the focus of the present paper
Summary
Kashuba groups investigated genetic/epigenetic alterations in human cancers by a large-scale method, named the NotI-microarray, for more than fifteen years This method represents a comparative genome hybridization technology (Karolinska Institute International Patent WO02/086163 and PCT/ SE02/00788 [1]), based on hybridization of the NotI-linking libraries, produced from tumor and normal genomic DNA [2]. To determine both, the genetic (deletions, amplifications) and epigenetic (methy lation, demethylation) changes in the genomic DNA of the NotI-linked genes / loci, due to the sensitivity of the NotI restriction enzyme to a methylation status of CpG islands Using this technology, 181 NotI-linking clones from different regions of human chromosome 3 were analyzed in more, than 250 malignant tumor samples, derived from different organs and tissues. A function and a role of many other genes of chromosome 3, which show alterations in different human cancer types, were largely unknown, before the NotImicroarray study
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
